Literature DB >> 23701950

AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion.

Seung-Keun Hong1, Joseph H Jeong2, Andrew M Chan3, Jong-In Park4.   

Abstract

Upregulated ERK1/2 activity is often correlated with AKT activation during prostate cancer (PCa) progression, yet their functional relation needs elucidation. Using androgen-deprived LNCaP cells, in which ERK1/2 activation occurs in strong correlation with AKT activation, we found that AKT-mediated B-Raf regulation is necessary for ERK1/2 activation. Specifically, in response to androgen deprivation, AKT upregulated B-Raf phosphorylation at Ser445 without affecting A-Raf or C-Raf-1. This effect of AKT was abolished by Arg25 to Ala mutation or truncating (∆4-129) the pleckstrin homology domain of AKT, indicating that the canonical AKT regulation is important for this signaling. Intriguingly, although a constitutively active AKT containing N-terminal myristoylation signal could sufficiently upregulate B-Raf phosphorylation at Ser445 in LNCaP cells, subsequent MEK/ERK activation still required hormone deprivation. In contrast, AKT activity was sufficient to induce not only B-Raf phosphorylation but also MEK/ERK activation in the hormone refractory LNCaP variant, C4-2. These data indicate that androgen depletion may induce MEK/ERK activation through a synergy between AKT-dependent and -independent mechanisms and that the latter may become deregulated in association with castration resistance. In support, consistent AKT-mediated B-Raf regulation was also detected in a panel of PCa lines derived from the cPten(-/-)L mice before and after castration. Our results also demonstrate that AKT regulates androgen receptor levels partly via the Raf/MEK/ERK pathway. This study reveals a novel crosstalk between ERK1/2 and AKT in PCa cells.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23701950      PMCID: PMC3699957          DOI: 10.1016/j.yexcr.2013.05.008

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  60 in total

1.  Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation.

Authors:  C S Mason; C J Springer; R G Cooper; G Superti-Furga; C J Marshall; R Marais
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

2.  Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1.

Authors:  Mengwei Zang; Cynthia Hayne; Zhijun Luo
Journal:  J Biol Chem       Date:  2001-11-30       Impact factor: 5.157

3.  Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells.

Authors:  Robert E Bakin; Daniel Gioeli; Eric A Bissonette; Michael J Weber
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

4.  Positive and negative regulation of Raf kinase activity and function by phosphorylation.

Authors:  H Chong; J Lee; K L Guan
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

5.  B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms.

Authors:  Nancy H Tran; Xiaochong Wu; Jeffrey A Frost
Journal:  J Biol Chem       Date:  2005-02-14       Impact factor: 5.157

6.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.

Authors:  Nallasivam Palanisamy; Bushra Ateeq; Shanker Kalyana-Sundaram; Dorothee Pflueger; Kalpana Ramnarayanan; Sunita Shankar; Bo Han; Qi Cao; Xuhong Cao; Khalid Suleman; Chandan Kumar-Sinha; Saravana M Dhanasekaran; Ying-bei Chen; Raquel Esgueva; Samprit Banerjee; Christopher J LaFargue; Javed Siddiqui; Francesca Demichelis; Peter Moeller; Tarek A Bismar; Rainer Kuefer; Douglas R Fullen; Timothy M Johnson; Joel K Greenson; Thomas J Giordano; Patrick Tan; Scott A Tomlins; Sooryanarayana Varambally; Mark A Rubin; Christopher A Maher; Arul M Chinnaiyan
Journal:  Nat Med       Date:  2010-06-06       Impact factor: 53.440

7.  The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells.

Authors:  Seung-Keun Hong; Jin-Hwan Kim; Ming-Fong Lin; Jong-In Park
Journal:  Exp Cell Res       Date:  2011-08-16       Impact factor: 3.905

Review 8.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

9.  Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.

Authors:  Michael E Wright; Ming-Jer Tsai; Ruedi Aebersold
Journal:  Mol Endocrinol       Date:  2003-05-29

10.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Authors:  Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

View more
  7 in total

1.  The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.

Authors:  Lin Zhang; Shuping Yang; Xingcheng Chen; Seth Stauffer; Fang Yu; Subodh M Lele; Kai Fu; Kaustubh Datta; Nicholas Palermo; Yuanhong Chen; Jixin Dong
Journal:  Mol Cell Biol       Date:  2015-02-02       Impact factor: 4.272

2.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

3.  ERK1/2 can feedback-regulate cellular MEK1/2 levels.

Authors:  Seung-Keun Hong; Pui-Kei Wu; Mansi Karkhanis; Jong-In Park
Journal:  Cell Signal       Date:  2015-07-09       Impact factor: 4.315

4.  Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability.

Authors:  Pui-Kei Wu; Seung-Keun Hong; Wenjing Chen; Andrew E Becker; Rebekah L Gundry; Chien-Wei Lin; Hao Shao; Jason E Gestwicki; Jong-In Park
Journal:  Sci Signal       Date:  2020-03-10       Impact factor: 8.192

Review 5.  Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression.

Authors:  Adrian P Rybak; Robert G Bristow; Anil Kapoor
Journal:  Oncotarget       Date:  2015-02-10

6.  AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2.

Authors:  Hui-Ping Lin; Ching-Yu Lin; Chieh Huo; Yee-Jee Jan; Jen-Chih Tseng; Shih Sheng Jiang; Ying-Yu Kuo; Shyh-Chang Chen; Chih-Ting Wang; Tzu-Min Chan; Jun-Yang Liou; John Wang; Wun-Shaing Wayne Chang; Chung-Ho Chang; Hsing-Jien Kung; Chih-Pin Chuu
Journal:  Oncotarget       Date:  2015-09-29

Review 7.  Insights into Chemoresistance of Prostate Cancer.

Authors:  Wei Zhang; Yan Meng; Na Liu; Xiao-Fei Wen; Tao Yang
Journal:  Int J Biol Sci       Date:  2015-08-01       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.